Table 3.
Summary of data from studies of the suprascapular nerve block (n = 9).
| Study | Approach | n | Combination | Local anaesthetic | HDP diagnostic method | Total HDP incidence (%) | Change in ipsilateral HD excursion (%) | FEV1 reduction (%) | FVC reduction (%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Type | Volume (mL) | Concentration (%) | |||||||||
| Trabelsi et al. [68] | Posterior | 30 | SCB (15 mL of bupivacaine 0.25%) | Bupivacaine | 15 | 0.250 | Symptoms | 0.0 | |||
|
| |||||||||||
| Aliste et al. [67] | Posterior | 20 | ICB (10 mL levobupivacaine 0.25%), +epinephrine 5 g/mL | Levobupivacaine | 10 | 0.250 | US | 0.0 | |||
|
| |||||||||||
| Auyong et al. [82] | Anterior | 63 | N | Ropivacaine | 15 | 0.500 | US, PFTs | 13.0 | 10.0 | ||
|
| |||||||||||
| Gianesello [83] | Anterior | 19 | ICB (levobupivacaine 0.5% 10 ml) | Levobupivacaine | 10 | 0.500 | PFTs | 0.0 | 0.0 | ||
|
| |||||||||||
| Taha et al. [84] | Anterior | 36 | N | Ropivacaine | 25 | 0.500 | US | 5.6 | 0.0 | ||
|
| |||||||||||
| Ferré et al. [62] | Anterior | 42 | AXNB (10 mL 0.375% ropivacaine + 2 mg dexamethasone) | Ropivacaine | 10 | 0.375 | US | 40.0 | −17.20 | ||
| Posterior | 41 | AXNB (10 mL 0.375% ropivacaine + 2 mg dexamethasone) | Ropivacaine | 10 | 0.375 | US | 2.0 | −3.60 | |||
|
| |||||||||||
| Lim et al. [85] | Anterior | 20 | N | Ropivacaine | 15 | 0.500 | US, PFTs | −1.80 | 7.0 | 3.6 | |
| Posterior | 20 | N | Ropivacaine | 15 | 0.500 | US, PFTs | −1.20 | 5.3 | 6.8 | ||
|
| |||||||||||
| Petroff et al. [86] | Anterior | 24 | N | Ropivacaine | 10 | 1.000 | US | −7.69 | |||
|
| |||||||||||
| Rhyner et al. [87] | Anterior | 15 | AXNB (10 ml bupivacaine 0.5%/adrenaline 1 : 200,000) | Bupivacaine | 10 | 0.500 | US, PFTs | −10.00 | 5.3 | 2.4 | |
HD, hemidiaphragm; SCB, supraclavicular block; ICB, infraclavicular block.